Obesity drug significantly reduces the risk of infections and serious cardiovascular events
Peer-Reviewed Publication
Updates every hour. Last Updated: 28-Oct-2026 12:16 ET (28-Oct-2026 16:16 GMT/UTC)
People with type 2 diabetes and obesity may benefit from treatment with tirzepatide. Tirzepatide, marketed under the brand name Mounjaro, can reduce the risk of heart attacks and hospitalizations due to infections by about one-third each compared with a conventional diabetes medication. Researchers at the Technical University of Munich (TUM) and Harvard Medical School demonstrated this using health insurance data.